Recursion Pharmaceuticals Announces New Clinical Trial Enrollment for REC-1245 in Tumor Types with DNA Repair Vulnerabilities

Reuters
08/05
<a href="https://laohu8.com/S/RXRX">Recursion</a> Pharmaceuticals Announces New Clinical Trial Enrollment for REC-1245 in Tumor Types with DNA Repair Vulnerabilities

Recursion Pharmaceuticals Inc. has announced updates on its clinical programs, including the ongoing Phase 1/2 DAHLIA study for REC-1245, a potential first-in-class RBM39 degrader. This study is currently enrolling patient populations characterized by replication stress and DNA repair vulnerabilities. Additionally, Recursion has identified platinum-resistant ovarian cancer as the first combination cohort for its CDK7 inhibitor, REC-617, utilizing multi-omic and real-world patient data alongside causal AI modeling. The company reported these developments and financial results for the second quarter of 2025, highlighting their strategic use of advanced models and platform capabilities to enhance both internal and partnered programs. Results from these studies have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Recursion Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9506150-en) on August 05, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10